EDSAEdesa Biotech, Inc.vs its industry peers
A metric-by-metric comparison of Edesa Biotech, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EDSAEsta | $25M#3 | — | 2.9x#3 | — | -100.0%#4 | -16.5%#4 | — | -81.6%#6 | — | — | — | — |
| CYDY | — | — | — | — | -100.0%#4 | -1240.2%#8 | — | — | — | — | — | — |
| CYTOF | — | — | — | — | — | -96.4%#7 | — | -207.6%#7 | — | — | — | — |
| DERM | — | — | — | — | 11.1%#2 | 22.1%#3 | -13.3%#2 | -35.6%#3 | -30.3%#3 | — | -44.6%#1 | — |
| DRUG | $103M#2 | — | — | — | — | — | — | — | — | — | — | — |
| ECOC | — | — | — | — | 0.0%#3 | -61.3%#6 | -2416.0%#3 | -76.9%#4 | -68.5%#4 | — | — | — |
| ELTP | — | — | — | — | 77.1%#1 | 1140.0%#2 | 33.0%#1 | 42.8%#2 | 38.9%#1 | 5#1 | — | — |
| ENLV | $356M#1 | 0.1x#1 | 0.2x#1 | — | — | 8329.2%#1 | — | 63.9%#1 | -0.6%#2 | — | — | — |
| EOCN | $19M#4 | — | 1.5x#2 | — | — | -37.1%#5 | — | -80.9%#5 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-11-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice